S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Forget NVDA. Buy this A.I. stock instead (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:AXGN

AxoGen (AXGN) Stock Forecast, Price & News

$4.85
-0.14 (-2.81%)
(As of 09/22/2023 ET)
Compare
Today's Range
$4.63
$5.01
50-Day Range
$4.85
$8.95
52-Week Range
$4.63
$13.66
Volume
575,720 shs
Average Volume
231,283 shs
Market Capitalization
$208.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

AxoGen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
240.2% Upside
$16.50 Price Target
Short Interest
Bearish
3.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$188,900 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

622nd out of 963 stocks

Electromedical Equipment Industry

14th out of 22 stocks


AXGN stock logo

About AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc., together with its subsidiaries, develops and markets technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

AXGN Price History

AXGN Stock News Headlines

AxoGen (NASDAQ:AXGN) Raised to Buy at StockNews.com
StockNews.com Downgrades AxoGen (NASDAQ:AXGN) to Hold
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
JMP Securities Remains a Buy on AxoGen (AXGN)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
AxoGen (NASDAQ: AXGN)
AxoGen Q1 2023 Earnings Preview
AxoGen Full Year 2022 Earnings: EPS Beats Expectations
See More Headlines
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AXGN Company Calendar

Last Earnings
8/07/2023
Today
9/24/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXGN
Employees
394
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+240.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-28,950,000.00
Pretax Margin
-15.86%

Debt

Sales & Book Value

Annual Sales
$138.58 million
Book Value
$2.39 per share

Miscellaneous

Free Float
39,885,000
Market Cap
$208.45 million
Optionable
Optionable
Beta
0.68
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Ms. Karen  ZaderejMs. Karen Zaderej (Age 61)
    Chairman, Pres & CEO
    Comp: $852.18k
  • Mr. Peter J. Mariani (Age 59)
    Exec. VP & CFO
    Comp: $532.5k
  • Mr. Michael Donovan (Age 58)
    VP of Operations
    Comp: $406.02k
  • Mr. Angelo G. Scopelianos Ph.D. (Age 68)
    Chief R&D Officer
    Comp: $540.91k
  • Ed Joyce
    Director of Investor Relations
  • Mr. Marc A. Began (Age 55)
    Exec. VP, Gen. Counsel & Chief Compliance Officer
  • Ms. Doris Quackenbush
    VP of Sales
  • Mr. Jens Schroeder Kemp
    Chief Marketing Officer
  • Ms. Maria D. MartinezMs. Maria D. Martinez (Age 55)
    Chief HR Officer
  • Mr. Erick DeVinney (Age 47)
    VP of Peripheral Nerve Science and Clinical Innovation













AXGN Stock - Frequently Asked Questions

Should I buy or sell AxoGen stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXGN shares.
View AXGN analyst ratings
or view top-rated stocks.

What is AxoGen's stock price forecast for 2023?

4 equities research analysts have issued 12 month target prices for AxoGen's shares. Their AXGN share price forecasts range from $15.00 to $20.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 240.2% from the stock's current price.
View analysts price targets for AXGN
or view top-rated stocks among Wall Street analysts.

How have AXGN shares performed in 2023?

AxoGen's stock was trading at $9.98 at the beginning of 2023. Since then, AXGN shares have decreased by 51.4% and is now trading at $4.85.
View the best growth stocks for 2023 here
.

Are investors shorting AxoGen?

AxoGen saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,410,000 shares, an increase of 21.6% from the August 15th total of 1,160,000 shares. Based on an average trading volume of 275,400 shares, the days-to-cover ratio is currently 5.1 days. Approximately 3.6% of the company's shares are sold short.
View AxoGen's Short Interest
.

When is AxoGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our AXGN earnings forecast
.

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) released its quarterly earnings results on Monday, August, 7th. The medical equipment provider reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.07. The medical equipment provider earned $38.16 million during the quarter, compared to analyst estimates of $39.40 million. AxoGen had a negative trailing twelve-month return on equity of 19.48% and a negative net margin of 15.86%.

What ETF holds AxoGen's stock ?

iShares Neuroscience and Healthcare ETF holds 5,003 shares of AXGN stock, representing 0.66% of its portfolio.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $154.00 million-$159.00 million, compared to the consensus revenue estimate of $157.43 million.

What is Karen Zaderej's approval rating as AxoGen's CEO?

19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (9.12%), BlackRock Inc. (7.66%), William Blair Investment Management LLC (3.75%), Perceptive Advisors LLC (3.41%), Silvercrest Asset Management Group LLC (2.15%) and State Street Corp (2.14%). Insiders that own company stock include Amy Mcbride Wendell, Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of AxoGen?

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $4.85.

How much money does AxoGen make?

AxoGen (NASDAQ:AXGN) has a market capitalization of $208.45 million and generates $138.58 million in revenue each year. The medical equipment provider earns $-28,950,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does AxoGen have?

The company employs 394 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The official website for the company is www.axogeninc.com. The medical equipment provider can be reached via phone at (386) 462-6800, via email at investorrelations@axogeninc.com, or via fax at 386-462-6801.

This page (NASDAQ:AXGN) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -